EPI Health Acquires Worldwide Rights to Rhofade from Aclaris

EPI Health, LLC, has acquired Rhofade (oxymetazoline hydrochloride) cream, 1% and related intellectual property assets from Aclaris Therapeutics, Inc. Rhofade is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

“We are excited about the acquisition of Rhofade and I am extremely proud of the EPI Health Team for this accomplishment,” says John Donofrio, President of EPI Health. “Rhofade aligns extremely well with our current product portfolio and enables EPI Health to better partner with our dermatology healthcare providers to successfully treat their patients with rosacea. The addition of Rhofade supports our continued goal of providing innovative medical dermatology products to dermatologists, and their patients, and emphasizes our overall commitment to the dermatology community.”

The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea. Persistent facial redness (erythema) is cited as the most common sign of rosacea and may resemble a flushing or sunburn that does not go away. Typical triggers include sun exposure, stress, weather, food, and exercise. In an NRS survey, nearly 90% of rosacea patients said this condition had lowered their self-confidence and self-esteem, and 41% reported it had caused them to avoid public contact or cancel social engagements.